| Dr Kiranchandra Maganlal Patel, MD | |
|
15419 Rocky Oak Ct, Houston, TX 77059-3128 | |
| (713) 436-9800 | |
| (713) 436-5551 |
| Full Name | Dr Kiranchandra Maganlal Patel |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 15419 Rocky Oak Ct, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053416453 | NPI | - | NPPES |
| 043657804 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | K6680 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Villagemd Of Southeast Texas Pa | 4587947346 | 271 |
News Archive
Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves dollars, a study by a University at Buffalo team has shown.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In recent decades, obesity has become a global problem. The disease goes hand in hand with a dramatic increase in the proportion of body fat. Researchers from the Max Planck Institute for Metabolism Research and the Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases at the University of Cologne have now succeeded in inhibiting a protein in mice that hampers activation of the useful "brown fat" in obese mice. When treated with inhibitors against this protein, obese mice exhibited a notable improvement of their glucose metabolism.
Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.
› Verified 8 days ago
| Entity Name | Villagemd Of Southeast Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841643327 PECOS PAC ID: 4587947346 Enrollment ID: O20170202000474 |
News Archive
Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves dollars, a study by a University at Buffalo team has shown.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In recent decades, obesity has become a global problem. The disease goes hand in hand with a dramatic increase in the proportion of body fat. Researchers from the Max Planck Institute for Metabolism Research and the Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases at the University of Cologne have now succeeded in inhibiting a protein in mice that hampers activation of the useful "brown fat" in obese mice. When treated with inhibitors against this protein, obese mice exhibited a notable improvement of their glucose metabolism.
Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kiranchandra Maganlal Patel, MD 9235 Katy Fwy, Ste 400, Houston, TX 77024-1507 Ph: (713) 461-2915 | Dr Kiranchandra Maganlal Patel, MD 15419 Rocky Oak Ct, Houston, TX 77059-3128 Ph: (713) 436-9800 |
News Archive
Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves dollars, a study by a University at Buffalo team has shown.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In recent decades, obesity has become a global problem. The disease goes hand in hand with a dramatic increase in the proportion of body fat. Researchers from the Max Planck Institute for Metabolism Research and the Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases at the University of Cologne have now succeeded in inhibiting a protein in mice that hampers activation of the useful "brown fat" in obese mice. When treated with inhibitors against this protein, obese mice exhibited a notable improvement of their glucose metabolism.
Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.
› Verified 8 days ago
Dr. Jeanette Ferrer, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6565 Fannin St., Main 577, Houston, TX 77030 Phone: 713-441-0428 | |
Dr. Bhavik Kumar, MD, MPH Family Medicine Medicare: Medicare Enrolled Practice Location: 4600 Gulf Fwy, Houston, TX 77023 Phone: 713-522-3976 Fax: 404-494-7435 | |
Nneka Okafor, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3701 Kirby Dr Ste 600, Houston, TX 77098 Phone: 713-798-8072 | |
Dr. Rolando R Maldonado I, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 548 Waugh Dr, Houston, TX 77019 Phone: 713-933-0501 | |
Scott H Hung, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10950 Resource Pkwy, Suite A, Houston, TX 77089 Phone: 281-484-5587 Fax: 281-506-1013 | |
Michael E. Buxbaum, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Weslayan St Ste 350, Houston, TX 77027 Phone: 713-533-1700 Fax: 713-533-1708 | |
Diana Atwal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6630 De Moss Dr, Houston, TX 77074 Phone: 713-272-2600 Fax: 713-272-5589 |